Lymphocyte subsets | Healthy controls (n = 30) | Phase | Silent infection (n = 30) | Minor infection (n = 27) | Severe infection (n = 34) | P-value |
---|---|---|---|---|---|---|
mDC/PBMC, % | 0.53 ± 0.13 | AP | 1.09 ± 0.34b | 0.81 ± 0.48b,c | 0.53 ± 0.24c,d | <0.0001a |
CP | 0.89 ± 0.43b,e | ND | 0.70 ± 0.30e | 0.0014a | ||
pDC/PBMC, % | 0.24 ± 0.11 | AP | 0.42 ± 0.21b | 0.39 ± 0.23b | 0.22 ± 0.14c,d | <0.0001a |
CP | 0.37 ± 0.22b | ND | 0.38 ± 0.12b,e | 0.0048a | ||
IFN-γ + CD4/CD3, % | 23.09 ± 6.03 | AP | 17.41 ± 7.75b | 16.13 ± 5.60b,d | 23.94 ± 6.72c,d | <0.0001a |
CP | 23.38 ± 6.81e | ND | 24.50 ± 8.73 | 0.0001a | ||
IFN-γ + CD8/CD3, % | 14.30 ± 5.65 | AP | 15.88 ± 8.17 | 12.53 ± 6.33 | 18.30 ± 8.23 | 0.0251 |
CP | 23.30 ± 8.94b,e | ND | 18.40 ± 8.66d | 0.0003a | ||
IL-17 + CD4/CD3, % | 2.06 ± 0.94 | AP | 1.74 ± 0.96 | 1.93 ± 0.89d | 2.84 ± 1.19b,c,d | 0.0004a |
CP | 3.37 ± 1.47b,e | ND | 3.04 ± 1.36b | 0.0002a | ||
IL-17 + CD8/CD3, % | 0.22 ± 0.17 | AP | 0.54 ± 0.33b | 0.40 ± 0.22b,d | 0.25 ± 0.18c | <0.0001a |
 |  | CP | 0.81 ± 0.34b | ND | 0.74 ± 0.69b | <0.0001a |